KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Total Debt (2016 - 2025)

Astrazeneca has reported Total Debt over the past 11 years, most recently at $27.8 billion for Q4 2025.

  • Quarterly results put Total Debt at $27.8 billion for Q4 2025, down 3.55% from a year ago — trailing twelve months through Dec 2025 was $27.8 billion (down 3.55% YoY), and the annual figure for FY2025 was $27.8 billion, down 3.55%.
  • Total Debt for Q4 2025 was $27.8 billion at Astrazeneca, down from $28.8 billion in the prior quarter.
  • Over the last five years, Total Debt for AZN hit a ceiling of $29.8 billion in Q4 2021 and a floor of $27.5 billion in Q4 2023.
  • Median Total Debt over the past 5 years was $28.3 billion (2022), compared with a mean of $28.4 billion.
  • Biggest five-year swings in Total Debt: surged 51.25% in 2021 and later decreased 5.08% in 2022.
  • Astrazeneca's Total Debt stood at $29.8 billion in 2021, then decreased by 5.08% to $28.3 billion in 2022, then dropped by 2.78% to $27.5 billion in 2023, then increased by 4.91% to $28.8 billion in 2024, then dropped by 3.55% to $27.8 billion in 2025.
  • The last three reported values for Total Debt were $27.8 billion (Q4 2025), $28.8 billion (Q4 2024), and $27.5 billion (Q4 2023) per Business Quant data.